HCC comprises∼ 80% of primary liver cancer. HCC is the only major cancer for which death
rates have not improved over the last 10 years. Most patients are diagnosed with advanced …

In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and
stemness features. In this context, tumor cells might undergo cell fate transition in response …

Hepatocellular carcinoma (HCC) has become one of the major diseases that are threatening
human health in the 21st century. Currently there are many approaches to treat liver cancer …

Despite advances in biomedicine, the incidence and the mortality of hepatocellular
carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages …

CD36 is highly expressed in diverse tumor types and its expression correlates with
advanced stages, poor prognosis, and reduced survival. In cancer cells, CD36: 1) increases …

Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). However,
it is difficult to alleviate this disease process using single-agent chemotherapy. Using …

Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. Onco Targets Ther. 2020; 13: 9721–9730. The
Editor and Publisher of OncoTargets and Therapy wish to retract the published article …

Nucleotide binding oligomerization domain 2 (NOD2) is a recognized innate immune sensor
which can initiate potent immune response against pathogens. Many innate immune …

AMP-activated protein kinase (AMPK) is a key regulator of cellular energy balance. In
response to metabolic stress, it acts to redress energy imbalance through promotion of ATP …

Inflammation is activated by diverse triggers that induce the expression of cytokines and
adhesion molecules, which permit a succession of molecules and cells to deliver stimuli and …